Munich – Biotechnology company MorphoSys AG has acquired all the shares in Sloning BioTechnology GmbH, Puchheim. The deal positions MorphoSys as a leading provider in the antibody technology market. Integration of Sloning BioTechnology boosts the company's expertise in the field of therapeutic and diagnostic antibodies. The value of the transaction was given as around EUR 19 million.
A team led by lead partner Stefan-Ulrich Müller advised the four private equity investors HBM BioVentures (Cayman) Ltd., Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG, KfW, and LBBW Venture Capital GmbH on all aspects of the transaction. The companies were the majority shareholders in Sloning BioTechnology GmbH, which was established in 2001.
Advisers CMS Hasche Sigle:
Stefan-Ulrich Müller, Corporate (Lead Partner)
Sebastian Wilhelm, Corporate
Dr Kurt Gratz, Tax
Jill Theuring, Corporate